TY - JOUR
T1 - CAR T-Cell-Based gene therapy for cancers
T2 - new perspectives, challenges, and clinical developments
AU - Jogalekar, Manasi P.
AU - Rajendran, Ramya Lakshmi
AU - Khan, Fatima
AU - Dmello, Crismita
AU - Gangadaran, Prakash
AU - Ahn, Byeong Cheol
N1 - Funding Information:
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (Ministry of Science and ICT) (NRF-2022R1A2C2005057).
Publisher Copyright:
Copyright © 2022 Jogalekar, Rajendran, Khan, Dmello, Gangadaran and Ahn.
PY - 2022/7/22
Y1 - 2022/7/22
N2 - Chimeric antigen receptor (CAR)-T cell therapy is a progressive new pillar in immune cell therapy for cancer. It has yielded remarkable clinical responses in patients with B-cell leukemia or lymphoma. Unfortunately, many challenges remain to be addressed to overcome its ineffectiveness in the treatment of other hematological and solidtumor malignancies. The major hurdles of CAR T-cell therapy are the associated severe life-threatening toxicities such as cytokine release syndrome and limited anti-tumor efficacy. In this review, we briefly discuss cancer immunotherapy and the genetic engineering of T cells and, In detail, the current innovations in CAR T-cell strategies to improve efficacy in treating solid tumors and hematologic malignancies. Furthermore, we also discuss the current challenges in CAR T-cell therapy and new CAR T-cell-derived nanovesicle therapy. Finally, strategies to overcome the current clinical challenges associated with CAR T-cell therapy are included as well.
AB - Chimeric antigen receptor (CAR)-T cell therapy is a progressive new pillar in immune cell therapy for cancer. It has yielded remarkable clinical responses in patients with B-cell leukemia or lymphoma. Unfortunately, many challenges remain to be addressed to overcome its ineffectiveness in the treatment of other hematological and solidtumor malignancies. The major hurdles of CAR T-cell therapy are the associated severe life-threatening toxicities such as cytokine release syndrome and limited anti-tumor efficacy. In this review, we briefly discuss cancer immunotherapy and the genetic engineering of T cells and, In detail, the current innovations in CAR T-cell strategies to improve efficacy in treating solid tumors and hematologic malignancies. Furthermore, we also discuss the current challenges in CAR T-cell therapy and new CAR T-cell-derived nanovesicle therapy. Finally, strategies to overcome the current clinical challenges associated with CAR T-cell therapy are included as well.
KW - CAR T-cell therapy
KW - gene therapy
KW - hematologic malignancies
KW - immunotherapy
KW - solid cancers
UR - http://www.scopus.com/inward/record.url?scp=85135490694&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135490694&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2022.925985
DO - 10.3389/fimmu.2022.925985
M3 - Review article
C2 - 35936003
AN - SCOPUS:85135490694
SN - 1664-3224
VL - 13
JO - Frontiers in immunology
JF - Frontiers in immunology
M1 - 925985
ER -